SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas

SLS stock rout deepens in July with Martin Shkreli questioning the timing of AML trial.

Shkreli reiterated a bearish stance on SLS while acknowledging a past bad call on Capricor after HOPE-3 trial results.

Shkreli suggested data from AML trial may not be available until Christmas.